# Chai Discovery Raises $400M Series C at $3.8B Valuation for AI Drug Discovery

> Chai Discovery has raised a 400 million dollar Series C at a 3.8 billion dollar valuation, led by Index Ventures, pushing its total funding past 600 million in just 11 months. The company builds models that forecast and redesign how molecules interact, and it has already lined up Eli Lilly, Pfizer, and Novartis as partners, which is the kind of validation that is harder to fake than a valuation. The technical claim underneath the raise is the reason to pay attention. Chai reports a 16 percent success rate at designing antibodies fully from scratch, which it says is roughly 100 times better than earlier computational approaches. De novo antibody design has been one of the genuinely hard problems in the field, so a jump of that magnitude, if it holds up in the wild, is significant. This lands in a week thick with AI-in-biology news, and it reinforces a pattern: the money is increasingly flowing to companies that can show a concrete lab result rather than a general promise that AI will someday transform medicine.

_Section: [AI Funding Tracker](https://www.wortins.com/funding) · Source: FierceBiotech · Published Tuesday, September 1, 2026_

## Wortins' read

Chai Discovery has raised a 400 million dollar Series C at a 3.8 billion dollar valuation, led by Index Ventures, pushing its total funding past 600 million in just 11 months. The company builds models that forecast and redesign how molecules interact, and it has already lined up Eli Lilly, Pfizer, and Novartis as partners, which is the kind of validation that is harder to fake than a valuation. The technical claim underneath the raise is the reason to pay attention. Chai reports a 16 percent success rate at designing antibodies fully from scratch, which it says is roughly 100 times better than earlier computational approaches. De novo antibody design has been one of the genuinely hard problems in the field, so a jump of that magnitude, if it holds up in the wild, is significant. This lands in a week thick with AI-in-biology news, and it reinforces a pattern: the money is increasingly flowing to companies that can show a concrete lab result rather than a general promise that AI will someday transform medicine.

## Source

[Read the full story at FierceBiotech](https://www.fiercebiotech.com/biotech/chai-brews-400m-series-c-fuel-ai-used-lilly-novartis-and-pfizer)

## Related coverage

- [Yellow.ai Announces SPAC Merger with Bluerock for $550M Public Offering](https://www.wortins.com/story/yellow-ai-announces-spac-merger-with-bluerock-for-550m-publi-a82f4e54) — [Business Standard](https://www.business-standard.com/content/press-releases-ani/yellow-ai-a-global-leader-in-enterprise-agentic-ai-to-go-public-via-550-million-merger-with-bluerock-acquisition-corp-126080301360_1.html)
- [Fireworks AI Raises $1.505B Series D at $17.5B Valuation](https://www.wortins.com/story/fireworks-ai-raises-1-505b-series-d-at-17-5b-valuation-32bcccad) — [Yahoo Finance](https://finance.yahoo.com/technology/ai/articles/fireworks-ai-raises-1-5-174637439.html)
- [Tesla Receives Nevada Autonomous Vehicle Network Company Permit](https://www.wortins.com/story/tesla-receives-nevada-autonomous-vehicle-network-company-per-1a032be5) — [Tesla/Nevada DMV](https://techstartups.com/2026/08/21)
- [Cheap Tokens, Costly Chips and a Missing AI Payoff](https://www.wortins.com/story/cheap-tokens-costly-chips-and-a-missing-ai-payoff-54f01241) — [Bloomberg](https://www.bloomberg.com/news/articles/2026-08-27/cheap-tokens-costly-chips-and-a-missing-ai-payoff)
- [Insilico Medicine's AI-Designed Drug Shows Positive Phase IIa Results](https://www.wortins.com/story/insilico-medicine-s-ai-designed-drug-shows-positive-phase-ii-e5d3ff05) — [VentureBeat](https://venturebeat.com/)
- [Travis Kalanick's Atoms Raises $1.7B for Industrial AI and Robotics](https://www.wortins.com/story/travis-kalanick-s-atoms-raises-1-7b-for-industrial-ai-and-ro-76e0ab3b) — [Yahoo Finance](https://finance.yahoo.com/technology/ai/articles/kalanick-atoms-raises-1-7b-212701007.html)

---

_Curated and written by [Wortins](https://www.wortins.com) — The daily AI briefing. Every story links to its original source; the "Wortins read" on each is our own original analysis. [About Wortins & our editorial approach](https://www.wortins.com/about)._